David Dearnaley is Professor of Uro-Oncology and lead clinician in the Academic Unit of Radiotherapy at The Royal Marsden (RMH) and The Institute of Cancer Research (ICR). He was Head of RMH Urology Unit from 1994 to 2006 and Chairman of RMH/ICR Committee for Clinical Research 2006 - 2013. He is the Prostate Theme Lead for the RMH/ICR Biomedical Research Centre. He was appointed NIHR Senior Investigator in 2008 - 2015 and is a member of the NHS R&D HTA Clinical Trials Board College of Experts (2012-). He has previously chaired both the MRC and NCRI Prostate Study Groups, as well as the MRC Radiotherapy Clinical Trials Group.
Principal areas of research are the development of conformal (CFRT), intensity modulated (IMRT), image-guided (IGRT) and hypofractionated radiotherapy treatments for prostate cancer. He has led phase III randomised trials to establish these in clinical practice and dose escalated CFRT has been incorporated in NICE guidance. Presently he leads associated translational programmes into the biophysics, radiogenomics and molecular pathology of radiation response and toxicity. Additionally he has a major interest in the systemic treatment of prostate cancer using hormonal therapies, chemotherapy, targeted isotopes and bone protective agents.